Description
About Tesamorelin (research peptide supply)
Tesamorelin is a synthetic 44-amino-acid peptide analog of growth hormone-releasing hormone (GHRH 1-44), modified with an N-terminal trans-3-hexenoyl group that improves stability against enzymatic degradation. Velora Research supplies tesamorelin as a lyophilized research peptide for in vitro and preclinical investigation by qualified laboratories and research professionals.
Every Tesamorelin 10mg vial supplied by Velora is independently verified by a third-party analytical laboratory using high-performance liquid chromatography (HPLC) and mass spectrometry. The batch-specific Certificate of Analysis is published on our COAs page and linked from this product page so researchers can confirm identity, purity, and molecular integrity before placing the compound into a study.
How tesamorelin behaves in research models
Published research describes tesamorelin as a GHRH receptor agonist that, in preclinical and clinical models, binds pituitary somatotroph cells and stimulates endogenous growth hormone (GH) secretion in a pulsatile, physiologic pattern. Downstream, this is associated with elevations in insulin-like growth factor 1 (IGF-1).
- Receptor target: GHRH receptor (GHRHR) on pituitary somatotrophs.
- Class: GHRH analog — distinct from growth-hormone secretagogues such as ipamorelin, GHRP-2, and GHRP-6, which act on the ghrelin receptor.
- Half-life: ~25–40 minutes in published clinical data, with sustained downstream effects on IGF-1.
- Discovery and development: Originally developed by Theratechnologies. Tesamorelin acetate is the active ingredient in EGRIFTA SV®, an FDA-approved injectable for the reduction of excess abdominal visceral adipose tissue in HIV-infected patients with lipodystrophy.
EGRIFTA SV® is a registered trademark of Theratechnologies. Velora Research’s Tesamorelin product is a research peptide supplied for in vitro and preclinical investigation only and is not affiliated with, endorsed by, or equivalent to EGRIFTA SV®. It is not for human use.
Key specifications
| Attribute | Specification |
| Research name | Tesamorelin (research peptide) |
| Chemical class | Stabilized GHRH (1-44) analog |
| Sequence | trans-3-hexenoyl-Tyr-Ala-Asp-Ala-Ile-Phe-Thr-Asn-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Met-Ser-Arg-Gln-Gln-Gly-Glu-Ser-Asn-Gln-Glu-Arg-Gly-Ala-Arg-Ala-Arg-Leu-NH2 |
| Available size | 10mg |
| Form | Lyophilized white powder |
| Purity | ≥99% (HPLC verified) |
| Molecular formula | C221H366N72O67S |
| Molecular weight | ~5135.87 g/mol |
| CAS number | 218949-48-5 |
| Storage (lyophilized) | -20°C, sealed, dry, dark |
| Storage (reconstituted) | 2-8°C, single-use aliquots recommended |
| Verification | Independent third-party HPLC + mass spectrometry per batch |
| COA access | Batch-specific COA at verify.janoshik.com (linked from this page) |
Tesamorelin cost & availability
Velora Research lists Tesamorelin 10mg at a transparent, single-tier price so research buyers can plan procurement without negotiating per inquiry:
| Vial size | Tesamorelin cost (USD) | Best for |
| 10mg | $60.00 | Pilot studies, receptor-binding assays, single-protocol pilots, and most preclinical research designs |
Tesamorelin cost can vary widely across research-peptide suppliers — from under $50 for vendors that don’t publish testing data, to several hundred dollars for clinical-grade Egrifta SV®. Velora’s $60 price reflects a research-grade compound that is independently HPLC- and mass-spec-verified at ≥99% purity, with a batch-specific COA accessible from the product page. Free US shipping applies on orders over $200, and most orders ship within 1–2 business days.
Why qualified researchers buy Tesamorelin from Velora Research
In a category where vendor quality varies dramatically, five things separate Velora Research from the field:
- Batch-level third-party COA. Each lot of Tesamorelin peptide is verified by an independent analytical lab using HPLC for purity and mass spectrometry for identity; the COA is downloadable from the product page and tied to the batch number printed on the vial.
- ≥99% HPLC-verified purity. Identity, purity, and molecular integrity confirmed before any batch is released for sale.
- Documented production protocols. Lyophilized under controlled conditions, sealed in inert atmosphere, traceable from synthesis through shipment.
- US-based 2-day shipping with cold-chain handling. Free over $200; orders processed within 1–2 business days.
- Compliance-first sales policy. Sales restricted to qualified laboratories, institutions, and research professionals. Research-use-only terms acknowledged at checkout.
Reconstitution & storage guidance (research use)
Velora Research’s Tesamorelin ships as a lyophilized powder. For in vitro studies, researchers typically reconstitute with bacteriostatic water (0.9% benzyl alcohol) at a concentration matched to the assay protocol. A common pilot ratio for a 10mg vial is 2 mL of BAC water, yielding a 5 mg/mL stock solution — adjust per your study design.
- Pre-reconstitution: store sealed at -20°C in a dry, dark environment. Avoid freeze-thaw cycles, which can degrade peptide integrity.
- Post-reconstitution: refrigerate at 2-8°C and use within the stability window established by the study protocol. Single-use aliquots reduce the risk of repeat exposure to room temperature.
- Handling: reconstitute and aliquot under sterile lab conditions with appropriate PPE.
Velora Research supplies bacteriostatic water as a separate product. Please refer to the peer-reviewed literature for protocol-specific reconstitution and handling parameters.
Tesamorelin vs. Sermorelin vs. Ipamorelin — research-context comparison
Researchers evaluating Tesamorelin for purchase often compare it to other growth-hormone-axis research peptides. Summary of how the three differ at the mechanism level, drawn from published research:
| Attribute | Tesamorelin | Sermorelin | Ipamorelin |
| Class | Stabilized GHRH (1-44) analog | Native GHRH fragment (1-29) | Selective GHRP (ghrelin receptor) |
| Receptor target | GHRH receptor | GHRH receptor | Ghrelin / GHS-R1a |
| Sequence length | 44 amino acids | 29 amino acids | 5 amino acids |
| Half-life | ~25–40 min | ~10–20 min | ~2 hours |
| FDA status (as of 2026) | Approved as EGRIFTA SV® (HIV lipodystrophy) | Not approved | Not approved |
| Mechanism profile in research | Sustained GHRH-receptor signaling | Short-acting GHRH-receptor signaling | Pulsatile, selective GH release without cortisol/prolactin spike |
Figures are drawn from published preclinical and clinical literature and are provided strictly for research-context comparison. Velora Research’s Tesamorelin, Sermorelin, and Ipamorelin products are supplied as research peptides for in vitro and preclinical investigation only — not as therapeutic products.
